Blood flow in the site of invasive moles within the myometrium after completion of chemotherapy: retrospective study of 33 patients

Objectives: Women with invasive moles (IMs) should continue with one or two cycles of chemotherapy until the level of human chorionic gonadotrophin (hCG) concentrations become normal. However, assessment of blood flow (BF) with Doppler ultrasonography (DU) in the myometrial mass after chemotherapic completion has not been reported. Materials and Methods:We intended to find out the outcomes of BF associated with different treatments during following-up by DU. The patients were employed different treatments (resection, chemotherapy or following-up). We use the Kaplan-Meier method to perform survival analysis between different groups. Results: Of 33 cases, two patients underwent resection of the mass, five patients had 1–2 additional cycles of chemotherapy, and the other 26 subjects had follow-up without additional treatment. There were no significant differences in initial hCG values, chemotherapy cycles, risk scores for IM, and diameter of masses between the two groups. However, differences in BF disappearance time in the two groups were detected, and hCG levels did not increase again in the two groups. Conclusions: These data suggest that IM patients can be followed up if DU reveals BF within masses in the uterine myometrium after completion of chemotherapy.

Doppler ultrasonography, invasive moles, blood flow, follow-up, hCG, retrospective study.

[1] “Gestational trophoblastic neoplasia”. In: Hoffman B.L., Schorge J.O., Schaffer J.I., Halvorson L.M., Bradshaw K.D., Marlene M. (eds). Williams Gynecology. 2nd ed. New York: McGraw-Hill, 2012, 321.

[2] Shih Ie M. Gestational trophoblastic neoplasia—pathogenesis and potential therapeutic targets. The lancet oncology. 2007;8: 642-50.

[3] Niemann I. Pei Hui, editor. Gestational Trophoblastic Disease. Diagnostic and Molecular Genetic Pathology. Current Clinical Pathology, series editor Antonio Giordano. Humana Press - Springer, New York, NY, USA. 1st Edition, 2011, ISBN 978-1-61779-393-6. Price 140euro. Hardcover. Acta obstetricia et gynecologica Scandinavica. 2012.

[4] Wells M. The pathology of gestational trophoblastic disease: recent advances. Pathology. 2007;39: 88-96.

[5] Bentley RC. Pathology of gestational trophoblastic disease. Clinical obstetrics and gynecology. 2003;46: 513-22.

[6] Hoffner L, Surti U. The genetics of gestational trophoblastic disease: a rare complication of pregnancy. Cancer Genetics. 2012;205: 63-77.

[7] Zhang XW, Zhu HB, Wu SY., Gao RL, Han JS, Wang XY et al. Distribution of the alleles at loci D16S539, D7S820, and D13S317 in hydatidiform mole genome from Chinese women and its relationship with clinical prognosis. Cancer Genet Cytogenet., 2006;164: 133-6.

[8] Yazaki-Sun S, Daher S, de Souza Ishigai MM., Alves MT, Mantovani TM, Mattar R. Correlation of c-erbB-2 oncogene and p53 tumor suppressor gene with malignant transformation of hydatidiform mole. J Obstet Gynaecol Res., 2006;32: 265-72.

[9] Tse KY, Chan KKL, Tam KF, Ngan H. An update on gestational trophoblastic disease. Obstetrics, Gynaecology & Reproductive Medicine. 2012;22: 7-15.

[10] Richter CE, Schwartz PE. Clinical Aspects of Gestational Trophoblastic Disease. Gestational Trophoblastic Disease. 2012: 179-94.

[11] Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376: 717-29.

[12] Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204: 11-8.

[13] Suprasert P, Manopunya M. Outcomes of Non-Metastatic Gestational Trophoblastic Neoplasia: Twelve Year Experience from a Northern Thailand Tertiary Care Center. Asian Pacific journal of cancer prevention: APJCP. 2015;16: 5913-6.

[14] Savage P, Kelpanides I, Tuthill M et al. Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol. 2015;137: 73-6.

[15] Yang J, Xiang Y, Wan X, Yang X. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol. 2006;103: 479-82.

[16] Boronow RC. Pelvic arteriography after chemotherapy of malignant trophoblastic disease. A case for caution. Obstet Gynecol. 1970;36: 675-9.

[17] Rodriguez N, Goldstein DP, Berkowitz RS. Treating gestational trophoblastic disease. Expert Opin Pharmacother. 2010;11: 3027-39.